Similar companies
Inhibikase Therapeutics Short Interest Snapshot
Inhibikase Therapeutics (IKT) has 18,518,754 shares short (13.27% of shares outstanding), roughly flat (-5.0%) from the prior period. The data is biweekly short interest reported to NASDAQ, with a built-in 2-week reporting lag — the same canonical figure short-interest trackers publish.
Recent IKT Short Interest Settlements
Each row is a biweekly snapshot — the cadence at which short interest is officially reported. The percent column is the change versus the prior settlement.
| Settlement Date | Shares Short | vs Prior | Days to Cover |
|---|---|---|---|
| Sep 15, 2026 | 18,518,754 | 47.49 | |
| Aug 31, 2026 | 19,489,554 | 47.39 | |
| Aug 14, 2026 | 19,666,839 | 35.53 | |
| Jul 31, 2026 | 19,135,668 | 21.49 | |
| Jul 15, 2026 | 18,261,416 | 16.95 | |
| Jun 30, 2026 | 19,421,754 | 17.38 | |
| Jun 15, 2026 | 18,894,930 | 34.36 | |
| May 29, 2026 | 18,509,827 | 24.57 |
Is Inhibikase Therapeutics Heavily Shorted?
"Days to cover" is the number of average trading days it would take shorts to buy back their position at recent volume. For IKT, that’s currently 47.49 days against 389,967 shares of average daily volume. Days to cover above 10 is squeeze-prone territory — if the stock catches a bid on news or earnings, shorts can’t exit quickly on normal volume.
IKT Short Interest in Context
Short interest is most useful read against the rest of the picture. Heavy shorting that lines up with insider selling and weakening Employee Business Outlook is a different story from heavy shorting with insider buying and a positive AI Score — the same number, very different setups.
The other signals on IKT right now:
- IKT AI Score — 47/100
- Employee Business Outlook — 0% positive (soft)
Read together, the picture is mixed — no decisive read from short interest plus the underlying signals. Worth tracking which side moves first.
For the other side of the position, see IKT insider transactions and congressional trades. For social-side conviction, see IKT overall sentiment and Reddit mentions.
Inhibikase Therapeutics Short Interest: Frequently Asked Questions
Inhibikase Therapeutics has 18,518,754 shares short — about 13.27% of its shares outstanding as of Sep 15, 2026. This figure is the official biweekly short interest report, which lags the settlement date by about two weeks — the same convention every short-interest tracker uses. (Note: "% of shares outstanding" runs slightly below the "% of float" you may see on MarketBeat or Fintel, since float excludes insider-held and restricted shares.)
At 18,518,754 shares short and 389,967 shares of average daily volume, IKT’s days-to-cover is 47.49. Days to cover above 10 is squeeze-prone territory — if the stock catches a bid on news or earnings, shorts can’t exit quickly on normal volume.
Short squeezes happen when heavily shorted stocks rally sharply, forcing shorts to buy back at higher prices. The classic warning signs are days-to-cover above ~5, rising short interest, and a catalyst that pushes price up. IKT currently meets the days-to-cover threshold. AltIndex tracks short interest alongside insider activity and sentiment — the same number reads very differently depending on what those other signals say.
The biweekly short interest figures come from NASDAQ’s official short interest report — the same source used by MarketBeat, Fintel, and Benzinga. The data is settlement-date-based, published twice a month, and lags about two weeks. For daily short-selling activity (a higher-frequency complement), see the short squeeze tracker.
Sign up and get more insights on Inhibikase Therapeutics.
See Inhibikase Therapeutics’s complete short interest history
Sign up to unlock 1-year and all-time charts for IKT, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREE
